Bio-Path (NASDAQ:BPTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The firm currently has a $4.50 price target on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 14.21% from the company’s current price.
According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. “
Separately, HC Wainwright dropped their target price on Bio-Path from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, November 16th.
Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, November 19th. The company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.83) by $0.03. As a group, analysts forecast that Bio-Path will post -3.04 EPS for the current fiscal year.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More: What is total return in investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.